Progression of follicular lymphoma and related entities: Report from the 2021 SH/EAHP Workshop.

OBJECTIVES The 2021 Society for Hematopathology and European Association for Haematopathology Workshop addressed the molecular and cytogenetic underpinnings of transformation and transdifferentiation in lymphoid neoplasms. METHODS Session 4, "Transformations of Follicular Lymphoma," and session 5, "Transformations of Other B-Cell Lymphomas," included 45 cases. Gene alteration analysis and expression profiling were performed on cases with submitted formalin-fixed, paraffin embedded tissue. RESULTS The findings from session 4 suggest that "diffuse large B-cell lymphoma/high-grade B-cell lymphoma with rearrangements of MYC and BCL2" is a distinct category arising from the constraints of a preexisting BCL2 translocation. TdT expression in aggressive B-cell lymphomas is associated with MYC rearrangements, immunophenotypic immaturity, and a dismal prognosis but must be differentiated from lymphoblastic -lymphoma. Cases in session 5 illustrated unusual morphologic and immunophenotypic patterns of transformation. Additionally, the findings support the role of cytogenetic abnormalities-specifically, MYC and NOTCH1 rearrangements-as well as single gene alterations, including TP53, in transformation. CONCLUSIONS Together, these unique cases and their accompanying molecular and cytogenetic data suggest potential mechanisms for and unusual patterns of transformation in B-cell lymphomas and indicate numerous opportunities for further study.

[1]  E. Campo,et al.  Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities , 2022, Virchows Archiv.

[2]  C. Mullighan,et al.  International Consensus Classification of acute lymphoblastic leukemia/lymphoma , 2022, Virchows Archiv.

[3]  E. Cohen,et al.  Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B-acute lymphoblastic leukemia/lymphoma , 2022, Haematologica.

[4]  W. Chan,et al.  Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma , 2022, Virchows Archiv.

[5]  R. Siebert,et al.  Classifying Germinal Center Derived Lymphomas—Navigate a Complex Transcriptional Landscape , 2022, Cancers.

[6]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[7]  L. Staudt,et al.  The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.

[8]  L. Medeiros,et al.  Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge , 2021, Modern Pathology.

[9]  S. Swerdlow,et al.  Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms , 2021, The American journal of surgical pathology.

[10]  C. Copie-Bergman,et al.  High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B , 2021, The American journal of surgical pathology.

[11]  C. Copie-Bergman,et al.  Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas , 2021, The American journal of surgical pathology.

[12]  K. Kirito,et al.  Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy , 2021, Virchows Archiv.

[13]  Cheng Cheng,et al.  Molecular Classification Improves Risk Assessment in Adult BCR-ABL1-negative B-ALL. , 2021, Blood.

[14]  A. Rosenwald,et al.  Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features , 2021, Virchows Archiv.

[15]  G. Ott,et al.  Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype , 2020, Haematologica.

[16]  D. Scott,et al.  Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. , 2020, Cancer discovery.

[17]  S. Pileri,et al.  A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas , 2020, iScience.

[18]  C. June,et al.  Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of epigenome. , 2020, Blood.

[19]  Ryan D. Morin,et al.  A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. , 2020, Cancer cell.

[20]  S. Barrans,et al.  Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. , 2020, Blood.

[21]  R. Advani,et al.  Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. , 2020, Blood advances.

[22]  S. Bens,et al.  Cryptic insertion of MYC exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of “MYC-negative” Burkitt lymphoma , 2020, Haematologica.

[23]  S. Barrans,et al.  Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit , 2019, Leukemia.

[24]  E. Campo,et al.  Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy , 2019, Journal of Experimental & Clinical Cancer Research.

[25]  Ryan D. Morin,et al.  --The double hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. , 2019, Blood.

[26]  A. Rosenwald,et al.  Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Klausen,et al.  Stratification by MYC expression has prognostic impact in MYC translocated B‐cell lymphoma—Identifies a subgroup of patients with poor outcome , 2019, European journal of haematology.

[28]  Ryan D. Morin,et al.  Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Barrans,et al.  Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Klapper,et al.  IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. , 2018, Blood.

[31]  Ryan D. Morin,et al.  High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. , 2018, Blood advances.

[32]  P. Brousset,et al.  Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements , 2018, Haematologica.

[33]  R. Bociek,et al.  Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations. , 2018, Human pathology.

[34]  E. Jabbour,et al.  High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma , 2018, Modern Pathology.

[35]  J. Cerhan,et al.  Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements , 2018, Haematologica.

[36]  Y. Oki,et al.  MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas , 2018, Modern Pathology.

[37]  A. Rosenwald,et al.  High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. , 2018, Blood.

[38]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[39]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[40]  L. Medeiros,et al.  Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma , 2017, Modern Pathology.

[41]  M. Keating,et al.  Richter transformation of CLL , 2016, Expert review of hematology.

[42]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[43]  A. Zelenetz,et al.  Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma , 2016, Cancer.

[44]  M. Konopleva,et al.  De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis , 2015, Pediatric hematology and oncology.

[45]  A. Rosenwald,et al.  The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum , 2015, Leukemia.

[46]  O. Elemento,et al.  Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients. , 2015, Human pathology.

[47]  R. Spang,et al.  Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma , 2014, Haematologica.

[48]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[49]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[50]  K. Ohshima,et al.  High frequency of t(14;18) in Hodgkin's lymphoma associated with follicular lymphoma , 2012, Pathology international.

[51]  A. Lauritzen,et al.  Double‐hit BCL2/MYC translocations in a consecutive cohort of patients with large B‐cell lymphoma – a single centre's experience , 2012, European journal of haematology.

[52]  L. Medeiros,et al.  B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome , 2012, Modern Pathology.

[53]  I. Lossos,et al.  Transformation of follicular lymphoma. , 2011, Best practice & research. Clinical haematology.

[54]  Philip M Kluin,et al.  Double-hit B-cell lymphomas. , 2011, Blood.

[55]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  A. Rosenwald,et al.  IgVH Mutational Status and Clonality Analysis of Richter's Transformation: Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma in Association With B-cell Chronic Lymphocytic Leukemia (B-CLL) Represent 2 Different Pathways of Disease Evolution , 2007, The American journal of surgical pathology.

[57]  F. Jardin,et al.  Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.

[58]  L. Kopper,et al.  Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome , 2004, Leukemia.

[59]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[60]  G. Ott,et al.  Pathology of lymphoma progression , 2001, Histopathology.

[61]  D. Head,et al.  Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group experience , 1999, Leukemia.

[62]  T. Lister,et al.  The t(14;18) chromosomal translocation and Bcl-2 protein expression in Hodgkin's disease. , 1994, Leukemia.

[63]  M. Raffeld,et al.  bcl-2 expression in Hodgkin's disease. Correlation with the t(14;18) translocation and Epstein-Barr virus. , 1993, American journal of clinical pathology.

[64]  M. Stetler-Stevenson,et al.  Involvement of the bcl-2 gene in Hodgkin's disease. , 1990, Journal of the National Cancer Institute.